Botulinum toxin: A review of the mode of action in migraine.
T P Do, J Hvedstrup, H W Schytz
https://pubmed.ncbi.nlm.nih.gov/29405250/Actively Recruiting
Led by Naval Medical Center Camp Lejeune · Updated on 2026-07-22
128
Participants Needed
1
Research Sites
25 weeks
Total Duration
Chronic migraine is a disabling condition that affects active duty military personnel and veterans, leading to impaired cognition and reduced quality of life. This study evaluates two treatments for chronic migraine onabotulinumtoxinA BOTOX4 and incobotulinumtoxinA XEOMIN4. The goal is to find an effective treatment that does not require refrigeration, which is important for members deployed in environments with limited storage options. Both treatments are botulinum toxins with comparable strength, and this Phase 3 randomized study compares their effects in adults with chronic migraine. Participants will be randomly assigned to receive either onabotulinumtoxinA or incobotulinumtoxinA. Each treatment involves 31 injections of 5 units each, totaling 155 units, administered in the head and neck at two sessions spaced 12 weeks apart. Injection sites include the forehead, temples, back of the head, upper neck, and shoulder-neck junction. The study measures changes in headache days and impact using validated questionnaires at baseline, 12 weeks, and 24 weeks. Participants will keep an electronic diary to record headache days, severity, and any adverse effects. Assessments include the Headache Impact Test-6 HIT-6 and the Migraine Specific Quality MSQ Questionnaire to evaluate headache impact and quality of life. The primary outcome is the change in headache days between 12 and 24 weeks after treatment. Secondary outcomes include changes in headache impact and health-related quality of life. The study lasts at least 24 weeks, with ongoing monitoring of participant experience and safety.
CONDITIONS
BOTOX® vs. XEOMIN® for Chronic Migraine
J
Jacqueline S Buckley, PharmD
K
Keely C Klaumann, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Naval Medical Center Camp Lejeune
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | XEOMIN® | BOTOX® |
|---|---|---|
| What is it? | XEOMIN® is a purified botulinum toxin type A product, injected at similar anatomical targets for chronic migraine prevention. | BOTOX® is a purified botulinum toxin type A formulation, injected at specific head and neck sites to prevent chronic migraine headaches. |
| Role in trial | Tested as the investigational arm to evaluate efficacy and safety compared to BOTOX®. | Serves as the active comparator arm and benchmark for chronic migraine prevention. |
| Primary use | Used off-label in chronic migraine prevention, with growing evidence for benefit. | Approved and widely used for prevention of chronic migraine in adults. |
| How is it given? | XEOMIN® injections are given at similar anatomical points, according to trial protocol, over two clinic visits. | BOTOX® injections are administered at defined sites in the head and neck during clinic visits, typically every 12 weeks. |
| Evidence status | Emerging evidence, mainly from prospective and observational studies, suggests XEOMIN® may help reduce headache burden in chronic migraine. | Strong randomized evidence confirms BOTOX® can reduce headache days and improve quality of life in chronic migraine. |
| Important risks | Similar adverse events as BOTOX®, including injection-site pain, muscle weakness, and rare serious effects; long-term safety is less well characterized in the migraine population. | Side effects may include neck pain, localized muscle weakness, temporary injection-site discomfort, and rarely more serious events; long-term safety in migraine is well established. |
| Important limitations | Current evidence is less extensive than for BOTOX®. Treatment schedules and optimal dosing are less well established, and some patients may not respond. | Therapeutic response varies; not all patients achieve meaningful migraine reduction. Repeat injections are needed, and some may develop resistance. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 weeks
Participants receive injections of either onabotulinumtoxinA (BOTOX4) or incobotulinumtoxinA (XEOMIN4) in the head and neck at two visits spaced 12 weeks apart.
2 visits for injections, 12 weeks apart
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
T P Do, J Hvedstrup, H W Schytz
https://pubmed.ncbi.nlm.nih.gov/29405250/H C Diener, D W Dodick, S K Aurora...
https://pubmed.ncbi.nlm.nih.gov/20647171/Jürgen Frevert, Dirk Dressler
https://pubmed.ncbi.nlm.nih.gov/21209727/A Carruthers, J Carruthers
https://pubmed.ncbi.nlm.nih.gov/18806905/Ariane K Kawata, Neel Shah, Jiat-Ling Poon...
https://pubmed.ncbi.nlm.nih.gov/33594686/Eugenia Yiannakopoulou
https://pubmed.ncbi.nlm.nih.gov/25613637/S K Aurora, D W Dodick, C C Turkel...
https://pubmed.ncbi.nlm.nih.gov/20647170/W J Kwong, D S Pathak
https://pubmed.ncbi.nlm.nih.gov/17376110/Rami Burstein, Rodrigo Noseda, David Borsook
https://pubmed.ncbi.nlm.nih.gov/25926442/Regina Rendas-Baum, Lisa M Bloudek, Gregory A Maglinte...
https://pubmed.ncbi.nlm.nih.gov/22797868/Naval Medical Center Camp Lejeune
Lead Sponsor